VarroMed

Pays: Union européenne

Langue: anglais

Source: EMA (European Medicines Agency)

Achète-le

Ingrédients actifs:

oxalic acid dihydrate, formic acid

Disponible depuis:

BeeVital GmbH

Code ATC:

QP53AG30

DCI (Dénomination commune internationale):

oxalic acid dihydrate / formic acid

Groupe thérapeutique:

Bees

Domaine thérapeutique:

Ectoparasiticides for topical use, incl. insecticides

indications thérapeutiques:

Treatment of varroosis (Varroa destructor) in honey bee colonies with and without brood

Descriptif du produit:

Revision: 3

Statut de autorisation:

Authorised

Date de l'autorisation:

2017-02-02

Notice patient

                                18
PARTICULARS TO APPEAR ON THE OUTER PACKAGE AND THE IMMEDIATE
PACKAGE
_MULTI-DOSE CONTAINER (BOTTLE)_
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
VarroMed 5 mg/ml + 44 mg/ml bee-hive dispersion for honey bees
Formic acid/oxalic acid dihydrate
2.
STATEMENT OF ACTIVE SUBSTANCES
Each ml contains:
ACTIVE SUBSTANCES:
Formic acid
5 mg
Oxalic acid dihydrate
44 mg
3.
PHARMACEUTICAL FORM
Bee-hive dispersion
4.
PACKAGE SIZE
555 ml
5.
TARGET SPECIES
Honey bees (
_Apis mellifera_
).
6.
INDICATION(S)
Treatment of varroosis (
_Varroa destructor_
) in honey bee colonies with and without brood.
7.
METHOD AND ROUTE(S) OF ADMINISTRATION
In-hive use.
Read the package leaflet before use.
Shake well before use.
8.
WITHDRAWAL PERIOD(S)
Withdrawal period(s): Honey: Zero days.
9.
SPECIAL WARNING(S), IF NECESSARY
19
During the application of the veterinary medicinal product, wear
protective clothing, acid-resistant
gloves and glasses.
Read the package leaflet before use.
10.
EXPIRY DATE
EXP
Shelf life after first opening container: 30 days.
Once opened, use by .…
11.
SPECIAL STORAGE CONDITIONS
Do not store above 25 °C.
Keep the bottle tightly closed.
Keep the bottle in the outer carton in order to protect from light.
12.
SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR
WASTE MATERIALS, IF ANY
Disposal: read the package leaflet.
13.
THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR
RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE
For animal treatment only.
14.
THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”
Keep out of the sight and reach of children.
15.
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
BeeVital GmbH
Wiesenbergstraße 19
A-5164 Seeham
AUSTRIA
16.
MARKETING AUTHORISATION NUMBER(S)
EU/2/16/203/001
17.
MANUFACTURER’S BATCH NUMBER
Batch
20
PARTICULARS TO APPEAR ON THE OUTER PACKAGE
_CARDBOARD BOX WITH 12 SINGLE-DOSE SACHETS_
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
VarroMed 75 mg + 660 mg bee-hive dispersion for honey bees
Formic acid/oxalic acid dihydrate
2.
STATEMENT OF AC
                                
                                Lire le document complet
                                
                            

Résumé des caractéristiques du produit

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
VarroMed 5 mg/ml + 44 mg/ml bee-hive dispersion for honey bees
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each ml contains:
ACTIVE SUBSTANCES:
Formic acid
5 mg
Oxalic acid dihydrate
44 mg (equivalent to 31.42 mg oxalic acid anhydrous)
EXCIPIENTS:
Caramel colour (E150d)
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Bee-hive dispersion.
Slightly brown to dark brown aqueous dispersion.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Honey bees (
_Apis mellifera_
).
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Treatment of varroosis (
_Varroa destructor_
) in honey bee colonies with and without brood.
4.3
CONTRAINDICATIONS
Do not use during nectar flow.
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
This veterinary medical product should only be used as part of an
integrated Varroa control
programme. Mite levels should be monitored regularly.
Efficacy was only investigated in hives with low to moderate mite
infestation rates.
4.5
SPECIAL PRECAUTIONS FOR USE
Special precautions for use in animals
Following treatment, worker bees with a protruding proboscis were
found. This might be associated
with insufficient access to drinking water. Ensure, therefore, that
treated bees have sufficient access to
drinking water.
The long-term tolerance of the veterinary medicinal product has only
been tested over 18 months, i.e.
a negative impact of the product on queens or colony development after
longer treatment periods
cannot be excluded. It is advised to check regularly that the queen is
present, but avoid disturbing the
hives in the days following treatment.
3
All colonies placed at the same location should be treated at the same
time to minimize the risk of re-
infestation.
Special precautions to be taken by the person administering the
veterinary medicinal product to
animals
−
This veterinary medicinal product is irritating to the skin and eyes.
Avoid contact with the skin,
eyes and mucous membranes. Per
                                
                                Lire le document complet
                                
                            

Documents dans d'autres langues

Notice patient Notice patient bulgare 11-01-2022
Rapport public d'évaluation Rapport public d'évaluation bulgare 10-04-2017
Notice patient Notice patient espagnol 11-01-2022
Rapport public d'évaluation Rapport public d'évaluation espagnol 10-04-2017
Notice patient Notice patient tchèque 11-01-2022
Rapport public d'évaluation Rapport public d'évaluation tchèque 10-04-2017
Notice patient Notice patient danois 11-01-2022
Rapport public d'évaluation Rapport public d'évaluation danois 10-04-2017
Notice patient Notice patient allemand 11-01-2022
Rapport public d'évaluation Rapport public d'évaluation allemand 10-04-2017
Notice patient Notice patient estonien 11-01-2022
Rapport public d'évaluation Rapport public d'évaluation estonien 10-04-2017
Notice patient Notice patient grec 11-01-2022
Notice patient Notice patient français 11-01-2022
Rapport public d'évaluation Rapport public d'évaluation français 10-04-2017
Notice patient Notice patient italien 11-01-2022
Rapport public d'évaluation Rapport public d'évaluation italien 10-04-2017
Notice patient Notice patient letton 11-01-2022
Rapport public d'évaluation Rapport public d'évaluation letton 10-04-2017
Notice patient Notice patient lituanien 11-01-2022
Rapport public d'évaluation Rapport public d'évaluation lituanien 10-04-2017
Notice patient Notice patient hongrois 11-01-2022
Rapport public d'évaluation Rapport public d'évaluation hongrois 10-04-2017
Notice patient Notice patient maltais 11-01-2022
Rapport public d'évaluation Rapport public d'évaluation maltais 10-04-2017
Notice patient Notice patient néerlandais 11-01-2022
Rapport public d'évaluation Rapport public d'évaluation néerlandais 10-04-2017
Notice patient Notice patient polonais 11-01-2022
Rapport public d'évaluation Rapport public d'évaluation polonais 10-04-2017
Notice patient Notice patient portugais 11-01-2022
Rapport public d'évaluation Rapport public d'évaluation portugais 10-04-2017
Notice patient Notice patient roumain 11-01-2022
Rapport public d'évaluation Rapport public d'évaluation roumain 10-04-2017
Notice patient Notice patient slovaque 11-01-2022
Rapport public d'évaluation Rapport public d'évaluation slovaque 10-04-2017
Notice patient Notice patient slovène 11-01-2022
Rapport public d'évaluation Rapport public d'évaluation slovène 10-04-2017
Notice patient Notice patient finnois 11-01-2022
Rapport public d'évaluation Rapport public d'évaluation finnois 10-04-2017
Notice patient Notice patient suédois 11-01-2022
Rapport public d'évaluation Rapport public d'évaluation suédois 10-04-2017
Notice patient Notice patient norvégien 11-01-2022
Notice patient Notice patient islandais 11-01-2022
Notice patient Notice patient croate 11-01-2022
Rapport public d'évaluation Rapport public d'évaluation croate 10-04-2017

Rechercher des alertes liées à ce produit

Afficher l'historique des documents